Cefepime
drugOn this page
Also known as BMY-28142CefepimaJ01DE01RenapimeVNRX-5022
Summary
Cefepime (CHEMBL186) is an approved small-molecule antibacterial drug (ATC J01DE01); indicated across 10 conditions including bacterial infectious disease and urinary tract infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J01DE01
- Indications: 10 conditions
- Clinical trials: 39
- Chemistry: 480.6 Da · C19H24N6O5S2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL186 |
| Name | Cefepime |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5479537 |
| ChEBI | CHEBI:478164 |
| ATC | J01DE01 |
| Molecular formula | C19H24N6O5S2 |
| Molecular weight | 480.6 |
| InChIKey | HVFLCNVBZFFHBT-ZKDACBOMSA-N |
SMILES: C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]
IUPAC name: (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
ChEBI definition: A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.
Pharmacological roles (ChEBI): antibacterial drug.
Also known as: BMY-28142, Cefepima, Cefepime, J01DE01, Renapime, VNRX-5022, cefepime, CEFEPIME
Parent form; salt/anhydrous children: CHEMBL1200962, CHEMBL1201736
Patent coverage: 6,370 distinct patent families (24,226 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Alpha-2B adrenergic receptor, Estrogen receptor, D(2) dopamine receptor, Histamine H3 receptor, Nuclear receptor subfamily 1 group I member 2.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ADRA2B | 9.3 | AC50 | 0.5 | nM | CHEMBL_ACT_25143943 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| urinary tract infection | 3 | MONDO:0100338 | EFO:0003103 |
| toxic shock syndrome | 3 | MONDO:0001881 | EFO:0006834 |
| pyelonephritis | 3 | MONDO:0006939 | EFO:1001141 |
| infectious disease | 2 | MONDO:0005550 | EFO:0005741 |
| hematopoietic and lymphoid system neoplasm | 2 | MONDO:0002334 | MONDO:0044881 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
| osteomyelitis | 0 | MONDO:0005246 | EFO:0003102 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 39.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 10 |
| PHASE1 | 9 |
| PHASE3 | 8 |
| PHASE2 | 8 |
| Not specified | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06954129 | PHASE4 | RECRUITING | A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients |
| NCT00358202 | PHASE4 | COMPLETED | Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia |
| NCT00609375 | PHASE4 | COMPLETED | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen |
| NCT02872038 | PHASE4 | COMPLETED | Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis |
| NCT04187755 | PHASE4 | COMPLETED | Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever |
| NCT04233996 | PHASE4 | UNKNOWN | Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients |
| NCT04948463 | PHASE4 | COMPLETED | Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia |
| NCT05079620 | PHASE4 | TERMINATED | Early Antibiotics After Aspiration in ICU Patients |
| NCT05156437 | PHASE4 | TERMINATED | Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) |
| NCT05977868 | PHASE4 | TERMINATED | Comparing Oral Versus Parenteral Antimicrobial Therapy |
| NCT00137787 | PHASE3 | COMPLETED | Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases |
| NCT01110408 | PHASE3 | TERMINATED | A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections |
| NCT01110421 | PHASE3 | TERMINATED | A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia |
| NCT02302092 | PHASE3 | TERMINATED | An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections |
| NCT02820987 | PHASE3 | COMPLETED | PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock |
| NCT03687255 | PHASE3 | COMPLETED | Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections |
| NCT03840148 | PHASE3 | COMPLETED | Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections |
| NCT04009772 | PHASE2/PHASE3 | UNKNOWN | Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section |
| NCT06048692 | PHASE3 | UNKNOWN | Cefepime and Unictam on Preventing Post-Cesarean Surgical Site Infections |
| NCT03078010 | PHASE2 | ACTIVE_NOT_RECRUITING | Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant |
| NCT06406114 | PHASE2 | RECRUITING | Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing |
| NCT02497781 | PHASE2 | COMPLETED | Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs) |
| NCT02732327 | PHASE2 | TERMINATED | Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer |
| NCT03485950 | PHASE2 | COMPLETED | Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam |
| NCT03680612 | PHASE2 | COMPLETED | Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI |
| NCT04983901 | PHASE2 | COMPLETED | PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN |
| NCT05826990 | PHASE2 | UNKNOWN | A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI |
| NCT02532140 | PHASE1 | COMPLETED | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime |
| NCT02709382 | PHASE1 | COMPLETED | A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment |
| NCT03332732 | PHASE1 | COMPLETED | VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers |
| NCT03680352 | PHASE1 | COMPLETED | Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects |
| NCT03680378 | PHASE1 | COMPLETED | Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF) |
| NCT03685084 | PHASE1 | COMPLETED | Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers |
| NCT03690362 | PHASE1 | COMPLETED | VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment |
| NCT03870490 | PHASE1 | COMPLETED | Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects |
| NCT04816968 | PHASE1 | UNKNOWN | Antibiotics Continuous Infusion at Home |
| NCT00497744 | Not specified | COMPLETED | A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis |
| NCT01852630 | Not specified | COMPLETED | Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure |
| NCT02680600 | Not specified | COMPLETED | Individualized Cefepime Dosing Study |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).